The cell therapy industry is in the early stages of growth and development, with only a few having secured regulatory approval. This approval comes with regulatory requirements that ensure safety, including patient outcomes data collection for up to 15 years post-infusion. While daunting, the strings attached to these first-generation therapy approvals help understand safety and…

Caribou Biosciences (NSDQ:CRBU) has announced the publication of data showing that its CRISPR hybrid RNA-DNA (chRDNA) guide technology supports better CRISPR associated protein 9 (Cas9) specificity compared with all-RNA guides. The Berkeley, California–based company’s technology thus enabled accuracy in intended genomic edits in cells while minimizing off-target events.  High Cas9 specificity is useful in the…